The proposal, which follows a representation from a stakeholder, suggests that testing at the prescribed laboratory may be waived for cough syrups being exported to the US, UK, Canada, EU, Japan, Australia, Singapore, Republic of Korea and Switzerland.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAmWe7I
via IFTTT
No comments:
Post a Comment